Abstract
AimsTo prospectively investigate the association between the number of prescribed drugs and the fracture risk in patients with type 2 diabetes. MethodsJapanese participants with type 2 diabetes (n = 4,706; 2,755 men, 1,951 postmenopausal women; mean age, 66 years) were followed for a median of 5.3 years and grouped on the basis of the number of prescribed drugs at baseline. The main outcomes were fractures at any anatomic site and fragility fractures (fractures at hip and spine sites). ResultsDuring follow-up, any fracture occurred in 662 participants. The overall age- and sex-adjusted fracture incidence rates per 1,000 person-years were 21.2 (0–2 drugs), 28.1 (3–5 drugs), 37.7 (6–8 drugs), and 44.0 (≥9 drugs) (p for trend < 0.001). Compared with 0–2 drugs, the multivariate-adjusted hazard ratios (HRs) (95% confidence intervals [CIs]) for fractures were 1.34 (1.07–1.68) for 3–5 drugs, 1.76 (1.37–2.26) for 6–8 drugs, and 1.71 (1.27–2.31) in ≥ 9 drugs. The multivariate-adjusted HR (95% CI) per increment in drugs was 1.05 (1.02–1.08) (p < 0.001). Similar tendencies were observed for fragility fractures. ConclusionsA greater number of prescribed drugs is associated with an increased bone fracture risk in patients with type 2 diabetes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
